Targeted Disease(s):
Pulmonary Fibrosis

Purpose of Study:

To evaluate the efficacy of two doses of GLPG1690 in addition to local standard of care compared to placebo in subjects with idiopathic pulmonary fibrosis (IPF) as evaluated by the rate of decline of forced vital capacity (FVC) over a period of 52 weeks.

Study Dates:
November 5, 2018 - December 15, 2021

Study Location:
Nationwide

Register for Trial

No upcoming events near you